Gilead Sciences

World Rank (Jan-05-2024)

133

Market Cap (Jan-05-2024)

105.265 Billion USD

World Rank (Jul-30-2023)

154

Market Cap (Jul-30-2023)

95.871 Billion USD

World Rank (Jan-07-2022)

180

Market Cap (Jan-07-2022)

89.387 Billion USD

World Rank (Jan-01-2021)

200

Market Cap (Jan-01-2021)

73.031 Billion USD

Company Rank in Country in 2023

Rank in USA in July-2023 is 88

Headquarters Country

USA

Nasdaq / NYSE Code

GILD

Market Cap (Mar-08-2026)

178.68

CEO

Daniel O'Day

Chairman

Daniel ODay

Founders

Michael L. Riordan

Employee Count

17,000

Employee Count as of Date

As on 2022

Headquarters City/State

California

World Region

Americas

World Subregion

Northern America

Annual Revenue in USD

27,116 Million USD

Annual Operating Income in USD

8,810 Million USD

Annual Net Income in USD

5,665 Million USD

Annual Results for Period Ending

Dec-2023 ending year

Total Assets in USD

62,125 Million USD

Total Liabilities in USD

39,376 Million USD

Total Equity in USD

22,749 Million USD

Balance Sheet for Period Ending

Dec-2023 ending year

Business Sector

Company Website

Gilead - Biopharmaceutical companies

Wikipedia

Yahoo

Yahoo @ Nasdaq

Facebook

Company Profile

GILEAD SCIENCES INC is world’s largest bio-pharmaceutical companies. As on Dec-2021, Gilead Sciences had 14,400 employees across six continents and headquarters is in USA,

As on 2022, GILEAD SCIENCES INC has 17,000 employees.

GILEAD SCIENCES INC annual revenue generated for period ending Dec-2022 was 27,281 million USD.

GILEAD SCIENCES INC annual net loss generated for period ending Dec-2022 was 4,592 million USD.

Gilead Sciences, Inc. is a research-based bio-pharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. Gilead Sciences strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products and pipeline of investigation drugs includes treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions.

GILEAD SCIENCES INC annual revenue generated for period ending Dec-2021 was 27,305 million USD.

Split of Annual Revenue by business segment for period ending Dec-2021:

Product sales: 27,008 million USD.
Royalty, contract and other revenues: 297 million USD.

GILEAD SCIENCES INC annual net income generated for period ending Dec-2021 was 6,225 million USD.

Total Assets as on Dec-2021 was 67,952 Million USD

Annual Results Summary

Gilead Sciences - Annual Results - Revenue and Net Income - in Million USD:

Year - Ending	Revenue	Operating Income	Net Income
Dec-2023	27,116	8,810	5,665
Dec-2022	27,281	10,974	4,592
Dec-2021	27,305	9,918	6,225
Dec-2020	24,689	9,927	123
Dec-2019	22,449	4,287	5,386
Dec-2018	22,127	8,200	5,455
Dec-2017	26,107	14,124	4,628

Balance Sheet Summary

Gilead Sciences - Balance Sheet Summary - in Million USD:

Year Ending:	Total Assets	Total Liabilities	Total Equity
Dec-2023	62,125	39,376	22,749
Dec-2022	63,171	41,962	21,209
Dec-2021	67,952	46,888	21,064
Dec-2020	68,407	50,205	18,202
Dec-2019	61,627	39,102	22,525
Dec-2018	63,675	42,288	21,387
Dec-2017	70,283	49,841	20,442

Founded Year

1987

Institutional Investors

Top 30 Institutional Holder Names in GILEAD SCIENCES as on SEP-30-2023

RANK	INSTITUTION NAME	DATE	SHARES HELD	CHANGE (SHARES)	CHANGE (%)	VALUE (IN 1,000S)
1	BLACKROCK INC.	09/30/2023	12,62,15,460	21,281	0.02%	$9,471,208
2	VANGUARD GROUP INC	09/30/2023	11,16,84,574	-16,84,076	-1.49%	$8,380,810
3	CAPITAL WORLD INVESTORS	09/30/2023	8,17,21,387	7,92,071	0.98%	$6,132,373
4	STATE STREET CORP	09/30/2023	5,88,85,047	-4,32,115	-0.73%	$4,418,734
5	CAPITAL RESEARCH GLOBAL INVESTORS	09/30/2023	5,79,13,708	14,039	0.02%	$4,345,845
6	DODGE & COX	09/30/2023	3,35,33,738	-4,46,019	-1.31%	$2,516,372
7	GEODE CAPITAL MANAGEMENT, LLC	09/30/2023	2,46,95,639	4,83,003	2.00%	$1,853,161
8	FMR LLC	09/30/2023	1,92,01,659	-8,69,555	-4.33%	$1,440,892
9	MORGAN STANLEY	09/30/2023	1,69,09,619	1,58,794	0.95%	$1,268,898
10	WELLINGTON MANAGEMENT GROUP LLP	09/30/2023	1,62,79,584	-3,61,918	-2.18%	$1,221,620
11	BANK OF NEW YORK MELLON CORP	09/30/2023	1,53,84,527	-20,68,395	-11.85%	$1,154,455
12	NORTHERN TRUST CORP	09/30/2023	1,49,22,488	5,04,475	3.50%	$1,119,784
13	NORGES BANK	12/31/2022	1,29,89,939	-1,35,591	-1.03%	$974,765
14	PARNASSUS INVESTMENTS, LLC	09/30/2023	1,19,15,371	-1,99,695	-1.65%	$894,129
15	NUVEEN ASSET MANAGEMENT, LLC	09/30/2023	1,14,14,149	16,14,798	16.48%	$856,518
16	GOLDMAN SACHS GROUP INC	09/30/2023	1,10,98,319	4,66,416	4.39%	$832,818
17	ROYAL BANK OF CANADA	09/30/2023	1,08,27,225	-3,27,946	-2.94%	$812,475
18	AMUNDI	09/30/2023	1,06,02,658	-3,16,824	-2.90%	$795,623
19	LEGAL & GENERAL GROUP PLC	09/30/2023	1,04,31,789	-3,87,292	-3.58%	$782,801
20	INVESCO LTD.	09/30/2023	1,03,63,359	-5,46,678	-5.01%	$777,666
21	ARROWSTREET CAPITAL, LIMITED PARTNERSHIP	09/30/2023	1,02,17,670	13,30,560	14.97%	$766,734
22	DIMENSIONAL FUND ADVISORS LP	09/30/2023	94,96,115	4,14,378	4.56%	$712,588
23	UBS ASSET MANAGEMENT AMERICAS INC	09/30/2023	93,55,861	4,50,908	5.06%	$702,064
24	CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM	09/30/2023	79,54,460	7,897	0.10%	$596,903
25	ALLIANCEBERNSTEIN L.P.	09/30/2023	72,01,826	-1,55,991	-2.12%	$540,425
26	CHARLES SCHWAB INVESTMENT MANAGEMENT INC	09/30/2023	71,94,007	-58,198	-0.80%	$539,838
27	WELLS FARGO & COMPANY/MN	09/30/2023	70,33,251	-1,93,608	-2.68%	$527,775
28	DEUTSCHE BANK AG\	09/30/2023	69,65,592	-11,67,311	-14.35%	$522,698
29	RENAISSANCE TECHNOLOGIES LLC	09/30/2023	64,43,384	-13,38,032	-17.20%	$483,512
30	LSV ASSET MANAGEMENT	09/30/2023	61,38,209	-1,54,260	-2.45%	$460,611